Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Johnson & Johnson Steps Up Medical Device Investment In China

This article was originally published in PharmAsia News

Executive Summary

Johnson & Johnson, known in China for its personal care and infant products, has of late stepped up efforts in its medical device business. Now the firm's second largest portfolio-with sales overtaking drugs and consumables for the past five consecutive years-medical device sales and profit have surpassed 36 percent growth annually. The firm also plans to acquire local companies in the sector to rapidly penetrate into the medium- and low-end medical device business, widely regarded as the first segment to benefit from China's health care reform. Johnson & Johnson is in the process of buying domestic firm DaBao Daily Chemicals; if successful, the 2.3 billion yuan deal will be J&J's biggest acquisition in China. (Click here for more - Chinese language)

You may also be interested in...

J&J Opens Device Plant In Suzhou, Expects Larger Piece Of China’s Growing Device Market

BEIJING - Johnson & Johnson's medical device manufacturing base started operation in China's southern city of Suzhou, the company announced April 22

US FDA Gives Wholesalers But Not Manufacturers More Time To Begin Verifying Saleable Returns

Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.

For Emergency Use, US FDA May Visit Rather Than Inspect COVID-19 Vaccine Manufacturing Sites

Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts